The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those ... Now, he’s a Mets’ batting ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

Ohio weight-loss clinics continue to be disciplined over alleged unsafe practices and false claims that they pass regulatory ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Gilead held dinners to promote its HIV medications at expensive restaurants that federal authorities claim were “wholly inappropriate” venues, Stat reported. Gilead said it settled to avoid the cost ...

MARION, Ind. (WISH) — Investigators with the Grant County Sheriff’s Office have filed charges for a $2,000 online scam that started on Facebook, but ended with funds transferred overseas.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Lastly, if you’re on or about to get on one of the new weight loss drugs, walk the walk and be patient. It took you quite a ...

If you’re living with overweight or obesity and are interested in exploring Zepbound as a treatment ... with standards of care and best practices, and we look into each brand’s reputation ...

But drugmakers and some health experts have pushed back against the practice because the FDA does ... the active ingredient in its weight loss drug Zepbound and diabetes treatment Mounjaro.

Eli Lilly sued Willow Health Services Inc., based in Austin, over allegations of unfair competition, false advertising and deceptive business practices ... and Zepbound, which treats obesity.